Emyria Limited (ASX:EMD) Announces Q4 2024 Quarterly Highlights
Emyria Limited (ASX:EMD) reports Q4 2024 achievements in mental health treatments, strategic partnerships, and a successful $2.525M placement.
Emyria Limited (ASX:EMD) reports Q4 2024 achievements in mental health treatments, strategic partnerships, and a successful $2.525M placement.
Clarity Pharmaceuticals (ASX:CU6) reports strong Q4 financials, significant trial progress, and entry into the ASX200 index.
Tissue Repair (ASX:TRP) reports strong Q4 2024 progress in drug trials and a 35% increase in TR Pro+® sales.
HITIQ Limited (ASX:HIQ) converts $1.6m in notes into shares and secures a new advisory mandate to enhance US investor relations.
Chimeric Therapeutics (ASX:CHM) advances clinical trials, secures $5M in funding, and appoints Dr Rebecca McQualter as CEO in Q4 report.
Arovella Therapeutics (ASX:ALA) secures $20 million placement, fully funding Phase 1 trials for ALA-101 and advancing its cancer therapy pipeline.
Vectus Biosystems Limited (ASX:VBS) releases its December 2024 Quarterly Activities Report, detailing clinical trial progress and a strong financial position.
Opthea Limited (ASX:OPT) releases Q2 FY25 Activity Report, detailing advancements in Phase 3 trials and financial developments including a R&D tax incentive.
Althea Group Holdings (ASX:AGH) announces $9.01 million in Q2 receipts, with ongoing governance improvements and operational strides in cannabis.
Superior Resources Limited (ASX:SPQ) reports notable progress in exploration, including new gold zones and funding for drilling initiatives.